Catalent (CTLT) Lifted to Buy at Zacks Investment Research
Catalent (NYSE:CTLT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The brokerage presently has a $49.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 14.46% from the stock’s previous close.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
A number of other equities analysts also recently issued reports on CTLT. Needham & Company LLC reissued a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Piper Jaffray Companies increased their price target on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 7th. BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Royal Bank of Canada started coverage on shares of Catalent in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $45.70.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The company had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. During the same period in the prior year, the firm earned $0.27 earnings per share. Catalent’s revenue was up 25.3% on a year-over-year basis. analysts anticipate that Catalent will post 1.53 EPS for the current year.
In other Catalent news, insider John R. Chiminski sold 181,458 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.70% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. Champlain Investment Partners LLC grew its holdings in shares of Catalent by 10.9% during the fourth quarter. Champlain Investment Partners LLC now owns 3,043,715 shares of the company’s stock valued at $125,036,000 after buying an additional 298,015 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Catalent by 755.3% during the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock valued at $108,108,000 after buying an additional 2,323,971 shares during the last quarter. Earnest Partners LLC grew its holdings in shares of Catalent by 0.5% during the third quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock valued at $102,601,000 after buying an additional 12,652 shares during the last quarter. Macquarie Group Ltd. grew its holdings in shares of Catalent by 15.8% during the third quarter. Macquarie Group Ltd. now owns 2,069,323 shares of the company’s stock valued at $82,607,000 after buying an additional 282,559 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in shares of Catalent by 4.3% during the fourth quarter. Brown Advisory Inc. now owns 2,031,955 shares of the company’s stock valued at $83,473,000 after buying an additional 83,441 shares during the last quarter. Hedge funds and other institutional investors own 99.82% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/catalent-ctlt-lifted-to-buy-at-zacks-investment-research/1881196.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.